Biomarin Pharmaceutical Inc.
Company Overview
BioMarin Pharmaceutical Inc. is a biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The company focuses on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases.
The company's commercial products include treatments for various genetic disorders such as phenylketonuria (PKU), mucopolysaccharidosis, and achondroplasia. BioMarin's business model centers on developing and marketing these specialized medications rather than interest-based activities.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $745.74m | $634.82m | - | $2.97m | 0.00% | 0.47% |
| June 30, 2024 | $712.03m | $595.15m | - | $3.57m | 0.00% | 0.60% |
| March 31, 2024 | $648.83m | $563.92m | - | $3.55m | 0.00% | 0.63% |
Company Impact
Help us evaluate Biomarin Pharmaceutical Inc.'s impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.